Literature DB >> 15016471

The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants.

Arthur J L Cooper1.   

Abstract

Glutamine transaminase K (GTK), which is a freely reversible glutamine (methionine) aromatic amino acid aminotransferase, is present in most mammalian tissues, including brain. Quantitatively, the most important amine donor in vivo is glutamine. The product of glutamine transamination (i.e., alpha-ketoglutaramate; alphaKGM) is rapidly removed by cyclization and/or conversion to alpha-ketoglutarate. Transamination is therefore "pulled" in the direction of glutamine utilization. Major biological roles of GTK are to maintain low levels of phenylpyruvate and to close the methionine salvage pathway. GTK also catalyzes the transamination of cystathionine, lanthionine, and thialysine to the corresponding alpha-keto acids, which cyclize to ketimines. The cyclic ketimines and several metabolites derived therefrom are found in brain. It is not clear whether these compounds have a biological function or are metabolic dead-ends. However, high-affinity binding of lanthionine ketimine (LK) to brain membranes has been reported. Mammalian tissues possess several enzymes capable of catalyzing transamination of kynurenine in vitro. Two of these kynurenine aminotransferases (KATs), namely KAT I and KAT II, are present in brain and have been extensively studied. KAT I and KAT II are identical to GTK and alpha-aminoadipate aminotransferase, respectively. GTK/KAT I is largely cytosolic in kidney, but mostly mitochondrial in brain. The same gene codes for both forms, but alternative splicing dictates whether a 32-amino acid mitochondrial-targeting sequence is present in the expressed protein. The activity of KAT I is altered by a missense mutation (E61G) in the spontaneously hypertensive rat. The symptoms may be due in part to alteration of kynurenine transamination. However, owing to strong competition from other amino acid substrates, the turnover of kynurenine to kynurenate by GTK/KAT I in nervous tissue must be slow unless kynurenine and GTK are sequestered in a compartment distinct from the major amino acid pools. The possibility is discussed that the spontaneous hypertension in rats carrying the GTK/KAT I mutation may be due in part to disruption of glutamine transamination. GTK is one of several pyridoxal 5'-phosphate (PLP)-containing enzymes that can catalyze non-physiological beta-elimination reactions with cysteine S-conjugates containing a good leaving group attached at the sulfur. These elimination reactions may contribute to the bioactivation of certain electrophiles, resulting in toxicity to kidney, liver, brain, and possibly other organs. On the other hand, the beta-lyase reaction catalyzed by GTK may be useful in the conversion of some cysteine S-conjugate prodrugs to active components in vivo. The roles of GTK in (a) brain nitrogen, sulfur, and aromatic amino acid/kynurenine metabolism, (b) brain alpha-keto acid metabolism, (c) bioactivation of certain electrophiles in brain, (d) prodrug targeting, and (e) maintenance of normal blood pressure deserve further study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016471     DOI: 10.1016/j.neuint.2003.12.002

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  44 in total

Review 1.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Tyrosine aminotransferase contributes to benzylisoquinoline alkaloid biosynthesis in opium poppy.

Authors:  Eun-Jeong Lee; Peter J Facchini
Journal:  Plant Physiol       Date:  2011-09-23       Impact factor: 8.340

3.  Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.

Authors:  Arthur J L Cooper; Boris F Krasnikov; John T Pinto; Hank F Kung; Jianyong Li; Karl Ploessl
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2012-05-19       Impact factor: 2.231

Review 4.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

5.  Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures.

Authors:  Kenneth Hensley; Alexandar Christov; Shekhar Kamat; X Cai Zhang; Kenneth W Jackson; Stephen Snow; Jan Post
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

Review 6.  Metabolite damage and its repair or pre-emption.

Authors:  Carole L Linster; Emile Van Schaftingen; Andrew D Hanson
Journal:  Nat Chem Biol       Date:  2013-02       Impact factor: 15.040

7.  Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Anatol Bragin; Kym Faull; Duilio Cascio; Robert Damoiseaux; Matthew J Schibler; Alexander Pushkin
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-20       Impact factor: 4.219

Review 8.  Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.

Authors:  John T Pinto; Jeong-In Lee; Raghu Sinha; Melanie E MacEwan; Arthur J L Cooper
Journal:  Amino Acids       Date:  2010-04-10       Impact factor: 3.520

Review 9.  Imine reductases: a comparison of glutamate dehydrogenase to ketimine reductases in the brain.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2013-01-12       Impact factor: 3.996

Review 10.  α-Ketoglutaramate: an overlooked metabolite of glutamine and a biomarker for hepatic encephalopathy and inborn errors of the urea cycle.

Authors:  Arthur J L Cooper; Tomiko Kuhara
Journal:  Metab Brain Dis       Date:  2013-11-14       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.